
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at different targeted cancer drugs for mesothelioma that has continued to grow during chemotherapy or came back after chemotherapy.
One of the for mesothelioma is chemotherapy. But there is no standard treatment if the mesothelioma continues to grow during chemotherapy or comes back after.
Targeted cancer drugs work by targeting the differences that help a cancer cell to grow and divide.
In this trial researchers want to know if certain targeted drugs can treat mesothelioma that continues to grow or come back after chemotherapy.
There are 3 stages to this trial.
In the 1st stage the team looks at a piece of tissue from your mesothelioma. They are looking for certain substances () in the mesothelioma cells. You might be offered treatment as part of the MiST trial if your mesothelioma cells have 1 or more of these biomarkers.
In stage 2 the researchers are looking at different treatments for mesothelioma. Which treatment you have as part of the trial depends on which biomarkers are in your mesothelioma cells.
In the 3rd stage researchers are looking at the tissue samples () taken as part of the MiST trial. They are looking at the genes of these samples to try and work out why some drugs work and why some drugs stop working.
The aims of the trial are to find out:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
You cannot join this trial if any of these apply:
This is a phase 2 trial. The trial team are looking at different treatments arms.
The 1st treatment arm (MiST1) looked at rucaparib. This arm is now closed.
The 2nd treatment arm (MiST2) looked at abemaciclib. This arm is now closed.
The 3rd treatment arm (MiST3) looked at bemcentinib and pembrolizumab. This arm is now closed.
The 4th treatment arm (MiST4) looked at atezolizumab and bevacizumab. This arm is now closed.
MiST5
In MiST5 dostarlimab and niraparib.
Dostarlimab is a targeted drug called a cancer growth blocker. It works by blocking a protein called PDL1. Cancer cells need PDL1 to grow. By blocking PDL1 dostarlimab might slow the growth of mesothelioma.
You have dostarlimab as a drip into a vein. You have it once every 3 weeks for 12 weeks. You then have it every 42 days.
Niraparib is a targeted drug called a PARP inhibitor. PARP is a protein that helps cells to repair damaged DNA. Blocking PARP means that cancer cells cannot repair their DNA. This causes the cancer cells to die and so controlling the cancer's growth.
Niraparib is a capsule. You have it once a day every day. Your doctor will tell you how many to take. You can take them with or without food.
You continue to have treatment for 2 years. This is as long as it is helping and the side effects aren't too bad.
Samples
The team will ask your permission to obtain a piece of cancer tissue from when you were diagnosed. If this isn’t available you must agree to give a fresh sample ().
You might be asked to give another sample of tissue if your treatment stops working. You don’t have to agree to this if you don’t want to. You can still take part in the trial.
You also give blood samples during the trial.
Researchers will use these samples to find out more about mesothelioma and how to treat it.
You also give a poo sample before the start of treatment and at times during treatment. Researchers use these samples to help them understand more about the effect immunotherapies have on the natural found in your bowel.
You have some tests before taking part. These tests include:
You see the doctor often while having treatment. This is to see how you are and for blood tests.
You have a CT scan every 6 weeks for 24 weeks and then every 12 weeks.
After treatment you see the doctor at:
You have an emergency card (like a business card) that has the contact details of the trial team. You should contact them if you have any side effects.
The most common side effects of dostarlimab are:
The most common side effects of narparib are:
Your doctor or a member of the research team will talk to you about the side effects of atezolizumab and bevacizumab before you agree to take part.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Dean Fennell
Asthma + Lung UK
Experimental Cancer Medicine Centre (ECMC)
University of Leicester
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”